<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="letter">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Indian J Ophthalmol</journal-id>
      <journal-id journal-id-type="publisher-id">IJO</journal-id>
      <journal-title-group>
        <journal-title>Indian Journal of Ophthalmology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0301-4738</issn>
      <issn pub-type="epub">1998-3689</issn>
      <publisher>
        <publisher-name>Medknow Publications</publisher-name>
        <publisher-loc>India</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">19384026</article-id>
      <article-id pub-id-type="pmc">2683442</article-id>
      <article-id pub-id-type="publisher-id">IndianJOphthalmol-57-241</article-id>
      <article-id pub-id-type="doi">10.4103/0301-4738.49406</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Letters to the Editor</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Combined photodynamic therapy and intravitreal bevacizumab as primary treatment for subretinal neovascularization associated with type 2 idiopathic macular telangiectasia</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Rishi</surname>
            <given-names>Pukhraj</given-names>
          </name>
          <xref ref-type="aff" rid="AF0001"/>
          <xref ref-type="corresp" rid="cor1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Rishi</surname>
            <given-names>Ekta</given-names>
          </name>
          <xref ref-type="aff" rid="AF0001"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Shroff</surname>
            <given-names>Daraius</given-names>
          </name>
          <xref ref-type="aff" rid="AF0001"/>
        </contrib>
      </contrib-group>
      <aff id="AF0001">Shri Bhagwan Mahavir Vitreoretinal Services, Medical and Vision Research Foundations, Sankara Nethralaya, 18, College Road, Chennai - 600 006, Tamil Nadu, India</aff>
      <author-notes>
        <corresp id="cor1">Correspondence to Dr. Pukhraj Rishi, Shri Bhagwan Mahavir Vitreoretinal Services, Medical and Vision Research Foundations, Sankara Nethralaya, 18, College Road, Chennai - 600 006, India. E-mail: <email xlink:href="docrishi@yahoo.co.in">docrishi@yahoo.co.in</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <season>May-Jun</season>
        <year>2009</year>
      </pub-date>
      <volume>57</volume>
      <issue>3</issue>
      <fpage>241</fpage>
      <lpage>242</lpage>
      <permissions>
        <copyright-statement>&#xA9; Indian Journal of Ophthalmology</copyright-statement>
        <copyright-year>2009</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0/">
          <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
    </article-meta>
  </front>
  <body>
    <p>Dear Editor,</p>
    <p>The natural history of untreated subretinal neovascular membranes (SRNVM) associated with idiopathic macular telangiectasia (IMT) is generally poor with 81% of eyes in a series of 26 eyes having a final visual acuity of 20/200 or worse.[<xref ref-type="bibr" rid="CIT1">1</xref>] Photocoagulation and sub-retinal surgery for treatment of SRNVM associated with IMT have not shown good results.[<xref ref-type="bibr" rid="CIT2">2</xref><xref ref-type="bibr" rid="CIT3">3</xref>] Photodynamic therapy (PDT) and intravitreal bevacizumab have been used individually for treatment of such eyes;[<xref ref-type="bibr" rid="CIT4">4</xref><xref ref-type="bibr" rid="CIT5">5</xref>] Combination PDT and ranibizumab has also been reported.[<xref ref-type="bibr" rid="CIT6">6</xref>] However, there are no reports on combination PDT and intravitreal bevacizumab for such eyes.</p>
    <p>A 60-year-old gentleman presented with diminution of vision in the right eye for two months. Best corrected visual acuity (BCVA) was 20/600 in the right eye and 20/60 in the left eye. Fundus examination of both eyes revealed Type 2A IMT with SRNVM in the right eye.[<xref ref-type="bibr" rid="CIT7">7</xref>] Clinical findings were confirmed on fundus fluorescein angiography (FFA) and optical coherence tomography (OCT) [Figs. <xref ref-type="fig" rid="F0001">1</xref>, <xref ref-type="fig" rid="F0002">2</xref>]. The patient was informed about the various treatment options available and the &#x2018;off label&#x2019; nature of bevacizumab. The patient underwent PDT followed by intravitreal bevacizumab (1.25 mg/0.05 ml), the next day. At 12 weeks follow-up, visual acuity in the right eye improved to 20/200. Clinically, SRNVM appeared to be regressing. The FFA showed minimal leakage [<xref ref-type="fig" rid="F0003">Fig. 3</xref>] and OCT revealed increased retinal thickness [<xref ref-type="fig" rid="F0004">Fig. 4</xref>]. Intravitreal bevacizumab (1.25 mg/0.05 ml) was repeated. At the last follow-up at 16 months, BCVA was maintained at 20/200 with a scarred SRNVM [<xref ref-type="fig" rid="F0005">Fig. 5</xref>].</p>
    <fig id="F0001" position="float">
      <label>Figure 1</label>
      <caption>
        <p>Color fundus picture (right) reveals perifoveal retinal opacification, refractile crystalline deposits and SRNVM temporal to the fovea along with ILM striae suggestive of proliferative Type 2 idiopathic macular telangiectasia. Fundus fluorescein angiography (left) reveals intense leakage from the SRNVM</p>
      </caption>
      <graphic xlink:href="IndianJOphthalmol-57-241-g001"/>
    </fig>
    <fig id="F0002" position="float">
      <label>Figure 2</label>
      <caption>
        <p>At presentation, optical coherence tomography reveals increased retinal thickening overlying the SRNVM with subretinal fluid (SRF)</p>
      </caption>
      <graphic xlink:href="IndianJOphthalmol-57-241-g002"/>
    </fig>
    <fig id="F0003" position="float">
      <label>Figure 3</label>
      <caption>
        <p>At 12 weeks, fundus fluorescein angiography reveals persisting leakage from the SRNVM</p>
      </caption>
      <graphic xlink:href="IndianJOphthalmol-57-241-g003"/>
    </fig>
    <fig id="F0004" position="float">
      <label>Figure 4</label>
      <caption>
        <p>At 12 weeks, optical coherence tomography reveals increased retinal thickening overlying the SRNVM</p>
      </caption>
      <graphic xlink:href="IndianJOphthalmol-57-241-g004"/>
    </fig>
    <fig id="F0005" position="float">
      <label>Figure 5</label>
      <caption>
        <p>Color fundus picture (a) at the last follow-up reveals a completely regressed SRNVM. Optical coherence tomography (b) shows a high-reflective, scarred subretinal membrane</p>
      </caption>
      <graphic xlink:href="IndianJOphthalmol-57-241-g005"/>
    </fig>
    <p>PDT with verteporfin reportedly maintains baseline vision in such eyes.[<xref ref-type="bibr" rid="CIT4">4</xref>] Potter <italic>et al.</italic> reported an average of 2.4 PDT treatments for cessation of leakage.[<xref ref-type="bibr" rid="CIT4">4</xref>] Intravitreal bevacizumab has been reported to improve visual outcome and reduce leakage in these cases.[<xref ref-type="bibr" rid="CIT5">5</xref>] Bevacizumab would have a beneficial effect on SRNVM in IMT due to its location above the retinal pigment epithelium (RPE) and the presence of anastomotic retinal vascular connections which could facilitate the concentration of the dye in the SRNVM.[<xref ref-type="bibr" rid="CIT5">5</xref>] Although vascular endothelial growth factor (VEGF) inhibition alone could prevent neovascularization at an early developmental stage, once neovascular beds are established they are unlikely to regress with anti-VEGF therapy alone. At this stage, a combined approach using a non-thermal laser has been seen to be beneficial. Bevacizumab is a larger molecule (molecular weight &#x2248; 150 kD) with a slightly longer intravitreal half-life of 4.9 days as compared to three days for ranibizumab (molecular weight &#x2248; 50 kD). Also, bevacizumab is available at a fraction of the cost of ranibizumab. Hence, a combination of PDT with bevacizumab may in some way, score over a combination of PDT with ranibizumab in such eyes. In conclusion, combination therapy using PDT and bevacizumab appears to be a promising approach in the primary management of SRNVM secondary to IMT.</p>
  </body>
  <back>
    <ref-list>
      <title>References</title>
      <ref id="CIT1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Engelbrecht</surname>
              <given-names>NE</given-names>
            </name>
            <name>
              <surname>Aaberg</surname>
              <given-names>TM</given-names>
              <suffix>Jr</suffix>
            </name>
            <name>
              <surname>Sung</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Lewis</surname>
              <given-names>ML</given-names>
            </name>
          </person-group>
          <article-title>Neovascular membranes associated with idiopathic juxtafoveolar telangiectasis</article-title>
          <source>Arch Ophthalmol</source>
          <year>2002</year>
          <volume>120</volume>
          <fpage>320</fpage>
          <lpage>4</lpage>
          <pub-id pub-id-type="pmid">11879135</pub-id>
        </element-citation>
      </ref>
      <ref id="CIT2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lee</surname>
              <given-names>BL</given-names>
            </name>
          </person-group>
          <article-title>Bilateral subretinal neovascular membrane in idiopathic juxtafoveolar telangiectasis</article-title>
          <source>Retina</source>
          <year>1996</year>
          <volume>16</volume>
          <fpage>344</fpage>
          <lpage>6</lpage>
          <pub-id pub-id-type="pmid">8865399</pub-id>
        </element-citation>
      </ref>
      <ref id="CIT3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Berger</surname>
              <given-names>AS</given-names>
            </name>
            <name>
              <surname>McCuen</surname>
              <given-names>BW</given-names>
            </name>
            <name>
              <surname>Brown</surname>
              <given-names>GC</given-names>
            </name>
            <name>
              <surname>Brownlow</surname>
              <given-names>RL</given-names>
            </name>
          </person-group>
          <article-title>Surgical removal of subfoveal neovascularization in idiopathic juxtafoveolar retinal telangiectasis</article-title>
          <source>Retina</source>
          <year>1997</year>
          <volume>17</volume>
          <fpage>94</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="pmid">9143035</pub-id>
        </element-citation>
      </ref>
      <ref id="CIT4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Potter</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Szabo</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Sarraf</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Michels</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Schmidt-Erfurth</surname>
              <given-names>U</given-names>
            </name>
          </person-group>
          <article-title>Photodynamic therapy for subretinal neovascularization in type 2A idiopathic juxtafoveolar telangiectasis</article-title>
          <source>Can J Ophthalmol</source>
          <year>2006</year>
          <volume>41</volume>
          <fpage>34</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="pmid">16462869</pub-id>
        </element-citation>
      </ref>
      <ref id="CIT5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mandal</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Venkatesh</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Abbas</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Vohra</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Garg</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Intravitreal bevacizumab (Avastin) for subretinal neovascularization secondary to type 2A idiopathic juxtafoveal telangiectasia</article-title>
          <source>Graefes Arch Clin Exp Ophthalmol</source>
          <year>2007</year>
          <volume>245</volume>
          <fpage>1825</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="pmid">17345090</pub-id>
        </element-citation>
      </ref>
      <ref id="CIT6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rishi</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Shroff</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Rishi</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Combined photodynamic therapy and intravitreal ranibizumab as primary treatment for subretinal neovascular membrane (SRNVM) associated with type 2 idiopathic macular telangiectasia</article-title>
          <source>Graefes Arch Clin Exp Ophthalmol</source>
          <year>2008</year>
          <volume>246</volume>
          <fpage>619</fpage>
          <lpage>21</lpage>
          <pub-id pub-id-type="pmid">18193448</pub-id>
        </element-citation>
      </ref>
      <ref id="CIT7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yannuzzi</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Bardal</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Freund</surname>
              <given-names>KB</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>KJ</given-names>
            </name>
            <name>
              <surname>Eandi</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Blodi</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Idiopathic macular telangiectasia</article-title>
          <source>Arch Ophthalmol</source>
          <year>2006</year>
          <volume>124</volume>
          <fpage>450</fpage>
          <lpage>60</lpage>
          <pub-id pub-id-type="pmid">16606869</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
